Stocks › SBHMY
SINO BIOPHARMACEUT SBHMY
US equityMarket cap rank #1132
$14.40 +$0.00 (0.00%)
Market closed · Nov 22, 2:00 pm ET
Open$14.23
Prev close$14.40
Day range$14.23 – $14.40
Volume200
Market cap$14.50B
P/E (TTM)37.9
Dividend yield2.13%
SBHMY Stock News
Headlines matching SINO BIOPHARMACEUT or the SBHMY ticker, most recent first.
- Sino Biopharm (1177.HK): Significant Improvement in Profitability; Breakthrough in Out-licensing of Innovative Drugs Positive
- Sino Biopharm (01177.HK): Platform-based innovation combined with global expansion drives the realization of big pharma status, ushering in a second growth curve Positive
- Hong Kong Stocks in Motion | Sino Biopharm (01177) rises nearly 4%; subsidiary reaches strategic cooperation with STADA on biosimilars, securing an upfront payment of up to €53 million Positive
- Sino Biopharm (1177.HK): Profitability significantly improved; innovation transformation and global partnerships continue to deliver results
- Sino Biopharm (01177 HK): Innovative drug business grows rapidly; BD efforts are accelerating realization.
- Sino Biopharm (01177.HK) 2026 Interim Report Commentary: Dual-Drive from Innovative Products and BD, with AI Empowering the Entire Business Chain
- Sino Biopharm (1177.HK): AI Deeply Empowers the R&D System; Two-Way BD Accelerates Globalization
- Sino Biopharm (01177.HK): BD deal successfully closed, with the innovative pipeline accelerating its realization.
- Sino Biopharm (1177.HK): Profit Quality Significantly Improved; Innovative Pipeline Accelerating Realization Positive
- Major Bank Ratings | Daiwa: Raises Sino Biopharm’s Target Price to HK$7.2, Reiterates "Buy" Rating Positive
- Sino Biopharm (1177.HK): BD Deals Are Being Realized, and the Platform's Innovative Value Has Been Validated
- SINO BIOPHARM: COMPLETION OF SHARE TRANSACTION - ACQUISITION OF 100% EQUITY INTEREST IN HYGIEIA INVOLVING THE ISSUE OF CONSIDERATION SHARES UNDER GENERAL MANDATE
- SINO BIOPHARM: NEXT DAY DISCLOSURE RETURN
- SINO BIOPHARM: NEXT DAY DISCLOSURE RETURN
- SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME
No comments yet — be the first to weigh in on SBHMY.
Sign in to join the discussion.